These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33516402)

  • 1. Atrial Fibrillation and Stroke.
    Essa H; Hill AM; Lip GYH
    Card Electrophysiol Clin; 2021 Mar; 13(1):243-255. PubMed ID: 33516402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study).
    Goldman ME; Pearce LA; Hart RG; Zabalgoitia M; Asinger RW; Safford R; Halperin JL
    J Am Soc Echocardiogr; 1999 Dec; 12(12):1080-7. PubMed ID: 10588784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioembolic Stroke: Past Advancements, Current Challenges, and Future Directions.
    Kato Y; Tsutsui K; Nakano S; Hayashi T; Suda S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation.
    Wiebe J; Bertog S; Franke J; Wettstein O; Lehn K; Hofmann I; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2014 Apr; 83(5):796-802. PubMed ID: 24327462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation and cardioembolic stroke.
    Ferro JM
    Minerva Cardioangiol; 2004 Apr; 52(2):111-24. PubMed ID: 15194993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary Stroke Prevention Following Embolic Stroke of Unknown Source in the Absence of Documented Atrial Fibrillation: A Clinical Review.
    Kotadia ID; Sim I; Mukherjee R; O'Hare D; Chiribiri A; Birns J; Bhalla A; O'Neill M; Williams SE
    J Am Heart Assoc; 2021 Jul; 10(13):e021045. PubMed ID: 34212774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation.
    Le D; Morelli R; Badhwar N; Lee RJ
    Expert Rev Cardiovasc Ther; 2015; 13(8):907-14. PubMed ID: 26070218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sealing the left atrial appendage: ready for prime time?
    El-Chami MF; Hoffman M; Lerakis S
    Am J Med Sci; 2007 May; 333(5):285-9. PubMed ID: 17505170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation.
    Black-Maier E; Piccini JP; Granger CB
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation.
    Grosset-Janin D; Barth E; Bertrand B; Detante O
    Rev Neurol (Paris); 2015 May; 171(5):426-32. PubMed ID: 25912470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Atrium and Embolic Stroke: Myopathy Not Atrial Fibrillation as the Requisite Determinant?
    Sajeev JK; Kalman JM; Dewey H; Cooke JC; Teh AW
    JACC Clin Electrophysiol; 2020 Mar; 6(3):251-261. PubMed ID: 32192674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation.
    Lam YY; Ma TK; Yan BP
    Int J Cardiol; 2011 Jul; 150(1):4-11. PubMed ID: 21112648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, Characteristics, and Clinical Course of Device-Related Thrombus After Watchman Left Atrial Appendage Occlusion Device Implantation in Atrial Fibrillation Patients.
    Kubo S; Mizutani Y; Meemook K; Nakajima Y; Hussaini A; Kar S
    JACC Clin Electrophysiol; 2017 Dec; 3(12):1380-1386. PubMed ID: 29759668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial).
    Main ML; Fan D; Reddy VY; Holmes DR; Gordon NT; Coggins TR; House JA; Liao L; Rabineau D; Latus GG; Huber KC; Sievert H; Wright RF; Doshi SK; Douglas PS
    Am J Cardiol; 2016 Apr; 117(7):1127-34. PubMed ID: 26993976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Link MS; Giugliano RP; Ruff CT; Scirica BM; Huikuri H; Oto A; Crompton AE; Murphy SA; Lanz H; Mercuri MF; Antman EM; Braunwald E;
    Circ Arrhythm Electrophysiol; 2017 Jan; 10(1):. PubMed ID: 28077507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.